Sarepta TherapeuticsSRPT
SRPT
About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Employees: 1,372
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
26% more call options, than puts
Call options by funds: $102M | Put options by funds: $81.3M
5% less repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 149
3.42% less ownership
Funds ownership: 92.04% [Q4 2024] → 88.62% (-3.42%) [Q1 2025]
7% less funds holding
Funds holding: 458 [Q4 2024] → 425 (-33) [Q1 2025]
29% less first-time investments, than exits
New positions opened: 72 | Existing positions closed: 101
48% less capital invested
Capital invested by funds: $10.7B [Q4 2024] → $5.53B (-$5.16B) [Q1 2025]
55% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 5 (-6) [Q1 2025]
Research analyst outlook
20 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
45%
downside
Avg. target
$47
160%
upside
High target
$98
439%
upside
20 analyst ratings
11 positive
55%
8 neutral
40%
1 negative
5%
JP Morgan Anupam Rama | 54%upside $28 | Overweight Maintained | 10 Jul 2025 |
HC Wainwright & Co. Mitchell Kapoor | 45%downside $10 | Sell Downgraded | 25 Jun 2025 |
Oppenheimer Hartaj Singh | 148%upside $45 | Outperform Maintained | 20 Jun 2025 |
Mizuho Uy Ear | 120%upside $40 | Outperform Maintained | 18 Jun 2025 |
Deutsche Bank David Hoang | 38%upside $25 | Hold Maintained | 17 Jun 2025 |
Financial journalist opinion
Based on 91 articles about SRPT published over the past 30 days
Neutral
GlobeNewsWire
15 hours ago
Lost Money on Sarepta Therapeutics, Inc.(SRPT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Neutral
GlobeNewsWire
16 hours ago
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.
Neutral
GlobeNewsWire
21 hours ago
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
23 hours ago
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
NEW YORK , July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025.
Neutral
GlobeNewsWire
1 day ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Neutral
GlobeNewsWire
1 day ago
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Neutral
PRNewsWire
1 day ago
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
NEW YORK , July 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
GlobeNewsWire
2 days ago
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta's top executives with violations of the Securities Exchange Act of 1934.
Neutral
GlobeNewsWire
2 days ago
SRPT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) - Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
Neutral
PRNewsWire
3 days ago
Class Action Announcement for Sarepta Therapeutics, Inc. (SRPT): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc.
RADNOR, Pa. , July 8, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the "Class Period").
Charts implemented using Lightweight Charts™